HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Primatene Mist First-Quarter Sales Grow 43% As Amphastar Expands Distribution

Executive Summary

Sales of Primatene Mist and other higher-margin products drive Amphastar's ifrst-quarter r5esults. The company continues to target a combined market worth around $10.5bn with seven generics in development.

You may also be interested in...



Primatene Mist Reaches Target Stores, Amphastar Spends Behind Reaching $65M Sales Target

In addition to distributing to Target stores, TV, radio and digital advertising and late-2020 start of sales at Kroger stores are driving Primatene Mist sales growth. The epinephrine aerosol inhaler's sales increased 186% in 2020 to $51.7m and 47% in Q4 to $13.4m.

Amphastar Pipeline Targets $10.5bn Market With Seven Generics

Amphastar announces that it has seven generic and three biosimilar products in development in order to target bigger markets. The company revealed that its insulin program is also developing towards interchangeable status. 

Amphastar Has First US Glucagon Rival

Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS151336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel